TTD | Drug: D04YLQ

Drug General Information
Drug ID	D04YLQ
Former ID	DNCL003313
Drug Name	AMG 334
Indication	Migraine [ICD9: 346; ICD10:G43]		Phase 2	[524809]
Company	Amgen
Target and Pathway
Target(s)	Calcitoningene-related peptide type 1 receptor	Target Info	Modulator	[544443]
KEGG Pathway	Neuroactive ligand-receptor interaction
KEGG Pathway	Vascular smooth muscle contraction
Reactome	G alpha (s) signalling events
Reactome	Calcitonin-like ligand receptors
WikiPathways	GPCRs, Class B Secretin-like
	Endothelin Pathways
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 524809	ClinicalTrials.gov (NCT02174861) A Study to Assess the Long-term Safety and Efficacy of AMG 334 in Chronic Migraine Prevention.. U.S. National Institutes of Health.
Ref 544443	EHMTI-0315. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor. J Headache Pain. 2014; 15(Suppl 1): G43.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.

Drug Information